Pre-Surgery drug combo shows promise against advanced melanoma
NCT ID NCT01972347
First seen Jan 04, 2026 · Last updated May 14, 2026 · Updated 23 times
Summary
This study tested whether giving two targeted drugs (dabrafenib and trametinib) for 12 weeks before surgery could shrink melanoma that has spread to lymph nodes. It involved 35 adults with stage IIIB-C BRAF V600 mutation-positive melanoma. The main goal was to see how much cancer remained in the removed tissue after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Melanoma Institute Australia
Wollstonecraft, New South Wales, 2065, Australia
Conditions
Explore the condition pages connected to this study.